Tafasitamab (Minjuvi)

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Tafasitamab (Minjuvi), 200 mg single-use vial, lyophilized powder for solution for IV infusion. Indication: In combination with rituximab and lenalidomide for the treatment of adult patients with Grade 1, 2, or 3a relapsed or refractory follicular lymphoma (FL).